Answers are grounded in this paper and cite their sources.
Liquid biopsy offers repeated, minimally invasive molecular profiling of cancer, but its clinical value depends on the analyte, analytical platform, and intended use. In this Review, we evaluate current liquid-biopsy technologies for diagnosis, prognosis, and treatment guidance, with a particular emphasize on tumor-derived extracellular vesicles (TDEVs) as a bridge between biomarker detection and therapeutic intervention. We examine genomic and epigenomic profiling, single-cell and single-vesicle analysis, and multi-omics integration as complementary approaches for assessing tumour burden, heterogeneity and treatment response. Circulating tumor DNA genotyping guides targeted therapy in selected advanced cancers, whereas many early-detection and vesicle-based applications require prospective validation. We highlight how the TDEV lipid bilayer protects diverse molecular cargo that reflects evolving tumour phenotypes and how TDEV-mediated communication contributes to metastasis, immune evasion and therapeutic resistance, creating opportunities to target pathogenic vesicle signalling. We also assess engineered vesicles from malignant and non-malignant cells as drug-delivery and cancer-vaccination platforms, while noting that tumour-derived carriers may retain oncogenic or immunosuppressive cargo. Most candidate vesicle biomarkers remain supported by retrospective studies, and therapeutic platforms are largely preclinical or in early clinical testing. We discuss the requirements for clinical translation, including reliable identification of tumour-derived vesicles, standardized workflows and prospective multicentre validation for diagnostics, and reproducible manufacturing, cargo characterization, potency testing and product-specific pharmacokinetic and safety evaluation for therapeutics. Finally, we consider how multimodal profiling and artificial intelligence might improve signal integration, and argue that clinical adoption will depend on demonstrating that vesicle-guided decisions and interventions improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: